Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant chemotherapy for non-small cell lung cancer

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Studies of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) did not provide a consistent disease-free survival or overall survival benefit in the 1980s and early 1990s. However, recently reported studies have changed the practice of NSCLC treatment, for which adjuvant chemotherapy is now considered the standard of care. This review outlines the issues that may have limited the detection of beneficial effects of adjuvant chemotherapy in early trials and provides detailed analysis of the results of recently published trials of adjuvant chemotherapy for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Eifel P, Axelson JA, Costa J, et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer. November 1–3, 2000. J Natl Cancer Inst 2001, 93:979–989.

    Article  PubMed  CAS  Google Scholar 

  2. Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321–326.

    PubMed  CAS  Google Scholar 

  3. Mountain CF: Revisions in the international system for staging lung cancer. Chest 1997, 111:1718–1723.

    PubMed  CAS  Google Scholar 

  4. Center for Disease Control: Lung cancer statistics. http://www.cdc.gov/cancer/lung/statistics.htm. Accessed October 18, 2005.

  5. Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998, 352:257–263.

  6. Feld R, Rubinstein L, Thomas PA: Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small cell lung cancer. J Natl Cancer Inst 1993, 85:299–306.

    Article  PubMed  CAS  Google Scholar 

  7. Niiranen A, Niitamo-Korhonen S, Kouri M, et al.: Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: a randomized study. J Clin Oncol 1992, 10:1927–1932.

    PubMed  CAS  Google Scholar 

  8. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899–909. Important study.

    Google Scholar 

  9. Scagliotti GV, Fossati R, Torri V, et al.: Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small cell lung cancer. J Natl Cancer Inst 2003, 95:1453–1461.

    PubMed  CAS  Google Scholar 

  10. The ALPI trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer. Adjuvant Lung Cancer Project Italy/European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Clin Cancer Res 2005, 11(Suppl 13):5011s-5016s.

    Google Scholar 

  11. Waller D, Peake MD, Stephens RJ, et al.: Chemotherapy for patients with non-small cell lung cancer. The surgical setting of the Big Lung Trial. Eur J Cardio Thorac Surg 2004, 26:173–182.

    Article  CAS  Google Scholar 

  12. Tada H, Tsuchiya R, Ichinose Y, et al.: A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer 2004, 43:167–173.

    Article  PubMed  Google Scholar 

  13. Arriagada R, Bergman B, Dunant A, et al.: Chemotherapy for patients with non-small cell lung cancer. N Engl J Med 2004, 350:351–360. Randomized 1867 patients to receive a cisplatin-based doublet as adjuvant chemotherapy versus observation, a very large trial for lung cancer; compared with the observation arm, patients who received chemotherapy had a 14% reduction in the risk of death (P < 0.03), resulting in an absolute survival benefit of 4.1% at 5 years; conclusion of this study is that a cisplatin-based doublet provides a benefit as adjuvant chemotherapy for NSCLC.

    Article  PubMed  Google Scholar 

  14. Strauss GM, Herndon J, Maddaus MA, et al.: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract 7019]. J Clin Oncol 2004, 22(Suppl):621. Patients with completely resected stage IB (T2N0) NSCLC (344 patients included) randomized to observation or carboplatin (AUC 6) and paclitaxel (200 mg/m2) every 3 weeks for four cycles as adjuvant chemotherapy; after a median followup of 34 months, there was a statistically significant improvement in overall survival (79.2% vs 69.6%, P = 0.028) and failure-free survival (68.8% vs 57.9%, P = 0.035) for the treatment arm; supports the use of carboplatin/paclitaxel in patients with completely resected stage IB NSCLC.

    Google Scholar 

  15. Winton T, Livingston R, Johnson D, et al.: Vinorelbine plus cisplatin vs. observation in resected non-smallcell lung cancer. N Engl J Med 2005, 352:2589–2597. Used cisplatin (50 mg/m2 on days 1 and 8 every 28 days, and navelbine 25 mg/m2 weekly for 16 weeks) versus observation in completely resected stage IB or II NSCLC (482 patients); statistically significant improvements in the treatment arm, compared with the observation arm, for recurrence rate (36% vs 49.6%) and 5-year overall survival (69% vs 54%) after a median follow-up of 5.3 years; supports the use of cisplatin and vinorelbine in resected NSCLC.

    Article  PubMed  CAS  Google Scholar 

  16. Douillard JY, Rosell R, Delena M, et al.: ANITA: Phase III adjuvant vinorelbine and cisplatin versus observation in completely resected (stage I-III) non-small cell lung cancer patients: final results after 70 month median follow-up [abstract 7013]. J Clin Oncol 2005, 23(Suppl 16S):624s. Important study.

    Google Scholar 

  17. Kato H, Ichinose Y, Ohta M, et al.: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004, 350:1713–1721.

    Article  PubMed  CAS  Google Scholar 

  18. Hamada C, Ohta M, Wada H, et al.: Survival benefit of oral UFT of adjuvant chemotherapy after completely resected non-small cell lung cancer. J Clin Oncol 2004, 22(Suppl 14):A70.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, 33612, Tampa, FL, USA

    Edward J. Crane MD

Authors
  1. Edward J. Crane MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Simon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crane, E.J., Simon, G. Adjuvant chemotherapy for non-small cell lung cancer. Curr. Treat. Options in Oncol. 7, 51–58 (2006). https://doi.org/10.1007/s11864-006-0031-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0031-8

Keywords

Search

Navigation